KemPharm (NSDQ:KMPH) said yesterday it inked a collaborative licensing deal with KVK Tech to obtain U.S. commercial rights to the company’s FDA-approved Apadaz drug.
Through the agreement, KemPharm is eligible to receive approximately $3.4 million in pre-launch payments and core cost reimbursement, including a $2 million milestone payment “related to the initial formulary adoption of Apadaz. The deal also includes an aggregate of up to $53 million in milestone payments related to net sales levels.
Read the whole story on our sister site, Drug Delivery Business News
The post KemPharm inks Apadaz licensing deal with KVK Tech appeared first on MassDevice.